Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
Cancer|July 9, 2026
Circulating tumor DNA in early breast cancer: Evidence, challenges, next stepsSerena Di Cosimo, Valentina Appierto, Carolina Reduzzi, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Clinical Breast Cancer|May 19, 2018
Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian ExperienceMaria Carmen De Santis, Francesca Bonfantini, Francesca Di Salvo, et al.
Clinical Breast Cancer|September 30, 2017
Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination?Maria Carmen De Santis, Francesca Bonfantini, Francesca Di Salvo, et al.
Journal of the National Cancer Institute|August 5, 2020
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine TherapyMaria Alice Franzoi, Daniel Eiger, Lieveke Ameye, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
Breast Cancer Research : BCR|October 28, 2020
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trialSerena Di Cosimo, Luca Porcu, Dominique Agbor-Tarh, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Advancing breast cancer therapy in the era of molecular diagnosticsMaria Grazia Carnevale, Riccardo Ray Colciago, Maria Carmen De Santis, et al.
Cancers|November 14, 2019
Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant ChemotherapySerena Di Cosimo, Valentina Appierto, Marco Silvestri, et al.
Pageof 16